• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

Pimecrolimus cream 1 percent shows less systemic absorptionthan tacrolimus 0.1 percent in treatment of atopic dermatitis

Washington - In the treatment of moderate-to-severe atopic dermatitis, pimecrolimus (Elidel) cream 1 percent is less likely than tacrolimus (Protopic) ointment 0.1 percent to be systemically absorbed, said Zoe Draelos, M.D., lead investigator of a blind treatment trial that compared systemic exposure levels of the two topical drugs.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.